GENUV’s proprietary drug screening platform technology is an efficient tool that enables the quick and precise identification of compounds that induce the neural stem cells in the human brain to differentiate into neurons.
Based on proprietary transgenic mouse technology, GENUV is developing a next-generation human antibody discovery platform technology that can serve the evolving demands of today’s global market that require mouse models with a greater variety of antibodies to identify complex targets.